What is Erlotinib?
Erlotinib 150mg tablet is an antitumor drug of the new generation, a potent inhibitor of epidermal development issue receptor tyrosine kinase that is accountable for the intracellular phosphorylation of epidermal development issue, the expression of which is observed on the surface of each regular and tumor cells. Inhibition of epidermal issue receptor phosphotyrosine inhibits the development of tumor cell lines and/or prospects to their death. Erlonat is a generic (analog) of the unique planning of Tarceva.
Erlonat is used for:
– locally innovative or metastatic non-modest cell lung cancer following failure of one or much more chemotherapy regimens;
– Locally distributed inoperable or metastatic pancreatic cancer as 1st line treatment in a blend with gemcitabine.
The drug is taken orally 1 p / day at least 1 hour just before or 2hrs following eating. With modest cell lung cancer, the drug is prescribed 150 mg every day, prolonged phrase.
In pancreatic cancer – 100mg every day, for an extended time in mixture with gemcitabine. If indications of illness progression seem, treatment ought to be discontinued. With caution must prescribe the drug to individuals with impaired liver perform. Security and efficacy in sufferers with hepatic insufficiency, renal dysfunction, and individuals beneath the age of 18 many years have not been studied. If required, dose adjustment is advised to be lowered steadily, every single time by 50 mg.
Side effects include:
On PS: anorexia, diarrhea, vomiting, stomatitis, dyspepsia, stomach soreness; gastrointestinal bleeding (some of which had been related to the concomitant use of warfarin or NSAIDs), liver dysfunction (including improved ALT, ACT, bilirubin), primarily transient, mild or reasonable severity, or related with liver metastases.
From the side of the organ of vision: conjunctivitis, dry keratoconjunctivitis; keratitis, a situation of transition to the corneal ulcer was exposed.
From the DS: a cough, shortness of breath; nosebleed; interstitial lung ailments (interstitial pneumonia, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory distress syndrome and pulmonary infiltration, which includes circumstances with a fatal final result).
On the central nervous program and peripheral NA: a headache, neuropathy, depression.
Dermatological reactions: rash, alopecia, dry skin, itching.
Other: fever, fatigue, chills, extreme infections without neutropenia), pneumonia, sepsis, fibrous irritation of the subcutaneous tissue, excess weight reduction.
The drug cannot be utilized: throughout pregnancy; throughout lactation; with improved sensitivity to erlotinib or to any element of the drug. With caution ought to prescribe the drug in violation of liver perform, sufferers beneath the age of 18 many years.
The use of erlotinib with other medicines can lead to the following consequences: inhibitors of the isoenzyme CYP3A4 (ketoconazole, etc.
minimize the metabolic process of erlotinib and boost its concentration in plasma; inducers of the isoenzyme CYP3A4 (rifampicin, etc.
improve the metabolic process of erlotinib and substantially decrease its concentration in the plasma. With the simultaneous use of erlotinib with warfarin and other coumarin derivatives, there was an improvement in MHO and bleeding, which includes gastrointestinal bleeding, some of which had been connected with the introduction of warfarin.
Keep the drug in a dry spot, protected from sun and inaccessible to youngster sat a temperature of15 to 30 ° C. Date of manufacture and shelf life are indicated on the packaging.